ALSO INCLUDES LINKS TO”

Novavax expresses fresh confidence in its vaccine

In wake of report on manufacturing difficulties, the Maryland-based drug firm vowed to file for emergency-use authorization by the end of the year.

AND

Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality

“We expect to complete multiple ongoing rolling regulatory submissions within the next couple of weeks in key markets, including the United Kingdom, Europe, Canada, Australia and New Zealand. We, along with SII, have already filed for authorization in India, Indonesia and The Philippines, as well as for Emergency Use Listing (EUL) with the World Health Organization (WHO). The WHO EUL will allow Novavax and SII to deliver on our combined commitment to the COVAX Facility for a cumulative 1.1 billion doses of our vaccine, around which we maintain ongoing conversations with CEPI, Gavi and UNICEF. Additionally, we expect to file for Emergency Use Authorization in the U.S. before the end of 2021.”

https://citizenfreepress.com/breaking/novavax-stock-craters-after-problems-with-vaccine/